Adam Brufsky, MD, PhD, UPMC Hillman Cancer Center

Articles by Adam Brufsky, MD, PhD, UPMC Hillman Cancer Center

Impact of Recent Clinical Data on Treatment for HER2+ MBC

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

CDK4/6 Inhibitors for Triple-Positive Breast Cancer

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

SOPHIA: Margetuximab + Chemotherapy for RR HER2+ MBC

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

DS-8201 and Tucatinib in HER2+ Metastatic Breast Cancer

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

Treatment Choice for Patient Relapsing With Brain Metastases

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

HER2CLIMB: Brain Metastases Data

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

Biomarker Data After Neoadjuvant Therapy for HER2+ Breast Cancer

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

HER2+ Early Stage Breast Cancer With Residual Invasive Disease

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

KAITLIN: T-DM1/Pertuzumab After Anthracycline-Based Adjuvant Therapy

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

TRAIN-2: Anthracyclines in HER2+ Breast Cancer

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

APHINITY and ExteNET Trials for Early-Stage Breast Cancer

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

HER2+ Early-Stage Breast Cancer

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

Guidelines and Approaches to HER2 Testing for Breast Cancer

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

Latest Updated Articles

TRAIN-2: Anthracyclines in HER2+ Breast Cancer
June 30th 2020
Biomarker Data After Neoadjuvant Therapy for HER2+ Breast Cancer
June 30th 2020
Guidelines and Approaches to HER2 Testing for Breast Cancer
June 30th 2020
HER2CLIMB: Brain Metastases Data
June 30th 2020
Treatment Choice for Patient Relapsing With Brain Metastases
June 30th 2020
HER2+ Early Stage Breast Cancer With Residual Invasive Disease
June 30th 2020

Trending on OncLive

FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer

Five Under 5: Top Oncology Videos for the Week of 8/31/26

CARiBOU Regimen Drives Complete Metabolic Responses in First-Line Mantle Cell Lymphoma

Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC

B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer